1 / 13

Analysis of Resistance-Associated Amino Acid Variants During Boceprevir Combination Treatment

This study explores the frequencies of resistance-associated amino acid variants (RAVs) detected by 454-sequencing during combination treatment with Boceprevir plus PEGINTRON/Ribavirin. The research investigates RAVs detected at baseline, decline in RAV viral load after a 4-week lead-in, and RAV frequencies at virologic failure. Conclusions discuss the significance of RAVs in interferon-responsive patients and their selection and decline during follow-up.

richardz
Download Presentation

Analysis of Resistance-Associated Amino Acid Variants During Boceprevir Combination Treatment

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Frequencies of Resistance-Associated Amino Acid Variants (RAVs) detected by 454-sequencing during Combination Treatment with Boceprevir Plus PEGINTRON (PegInterferon Alfa-2b)/Ribavirin

  2. Introduction

  3. Aim

  4. Methods

  5. RAVs Detected at Baseline

  6. 454-Sequence analysis of Baseline RAVs in Patients that Achieved SVR (SPRINT-1)

  7. Decline in RAV viral load after 4-week Lead-in (SPRINT-2, RESPOND-2)

  8. RAVs Detected at Baseline Decline Following PegIntron/RBV treatment;Interferon Responsive Patients (SPRINT-2)

  9. RAV Frequencies after 4-week P/R lead-in(SPRINT-2/RESPOND-2)

  10. RAVs At Virologic Failure

  11. T54S Variant Detected at Baseline; Interferon Responsive Patient (SPRINT-2)

  12. RAVs Selected at Virologic Failure Decline at Different Rates During Follow-up Period (SPRINT-1)

  13. Conclusions

More Related